CUPRHealthcare · Medical Instruments & SuppliesCUPR Stock Forecast: Cuprina Holdings (Cayman) Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 22 Aug 2026 — in the weakest quartile.
CUPR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cuprina Holdings (Cayman) Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CUPR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CUPR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CUPR appears on the weeks it earns a place.
CUPR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cuprina Holdings (Cayman) Ltd. (CUPR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 146.7×
- Price / book
- 1.8×
- EV / EBITDA
- −1.6×
Cheaper than 3% of US stocks
Cheaper than 48% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- 267.4%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −10568.3%
- Net margin
- −1.3%
Higher than 97% of US stocks
Higher than 2% of US stocks
Higher than 28% of US stocks
- Return on equity
- −1569.1%
- Return on assets
- −58.9%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Cuprina Holdings (Cayman) Ltd. (CUPR) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cuprina Holdings (Cayman) Ltd. has a market value of $7.3M and an enterprise value of $5.9M.
Cuprina Holdings (Cayman) Ltd. employs 10 people.
Data provided by Twelve Data
CUPR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cuprina Holdings (Cayman) Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CUPR stock
How does Ticker Nerd's model rank CUPR?
As at 22 Aug 2026, Cuprina Holdings (Cayman) Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the CUPR stock forecast for 2030?
No analyst covering Cuprina Holdings (Cayman) Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUPR are extrapolating price history, which says nothing about the business.
What does Cuprina Holdings (Cayman) Ltd. do?
Cuprina Holdings Ltd. is a biomedical and biotechnology company focused on advanced wound care and cosmeceutical products.
About Cuprina Holdings (Cayman) Ltd.
Cuprina Holdings Ltd. is a biomedical and biotechnology company focused on advanced wound care and cosmeceutical products. Headquartered in Singapore and founded in 2019, the company specializes in nature-based bioactive medical devices designed to manage and support healing of chronic wounds. Its flagship MEDIFLY line consists of medical-grade bio-dressing products made from sterile blowfly larvae, used as a biological debridement tool in maggot debridement therapy to remove non-viable tissue and promote wound bed preparation. Cuprina Holdings serves healthcare providers managing complex conditions such as diabetic foot ulcers, pressure injuries, and other hard-to-heal wounds, primarily in Asian markets including Singapore and Hong Kong. In addition to wound care, the company operates in the health and beauty segment, offering cosmeceutical products that apply its biomedical research and natural-materials expertise to skin-focused applications. Positioned within the medical instruments and supplies industry, Cuprina Holdings contributes a specialized, sustainable approach to chronic wound management and related skin health solutions.
CEO Mr. Yong Qi Quek · 10 employees · Singapore · https://www.cuprina.com.sg